Advertisement
Canada markets open in 7 hours 13 minutes

  • S&P/TSX

    22,375.83
    +116.63 (+0.52%)
     

  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     

  • DOW

    39,387.76
    +331.36 (+0.85%)
     

  • CAD/USD

    0.7309
    -0.0003 (-0.04%)
     

  • CRUDE OIL

    79.90
    +0.64 (+0.81%)
     

  • Bitcoin CAD

    86,066.48
    +1,602.56 (+1.90%)
     

  • CMC Crypto 200

    1,349.76
    -8.25 (-0.61%)
     

  • GOLD FUTURES

    2,364.30
    +24.00 (+1.03%)
     

  • RUSSELL 2000

    2,073.63
    +18.49 (+0.90%)
     

  • 10-Yr Bond

    4.4490
    -0.0430 (-0.96%)
     

  • NASDAQ futures

    18,222.75
    +8.25 (+0.05%)
     

  • VOLATILITY

    12.69
    -0.31 (-2.38%)
     

  • FTSE

    8,381.35
    +27.30 (+0.33%)
     

  • NIKKEI 225

    38,203.28
    +129.30 (+0.34%)
     

  • CAD/EUR

    0.6776
    -0.0002 (-0.03%)
     

Myriad Genetics to Release First Quarter Financial Results on May 3, 2023

Myriad Genetics, Inc.
·1 min read
Myriad Genetics, Inc.
Myriad Genetics, Inc.

SALT LAKE CITY, April 26, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Wednesday May 3, 2023 at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day after the market closes.

During the call, Myriad management will provide a financial overview and business update of the company’s performance for the period ending March 31, 2023.

Conference Call and Webcast
The dial-in number for domestic callers is 1-800-582-4086. International callers may dial 1-212-231-2905. All callers will be asked to reference reservation number 22026701. An archived replay of the call will be available for seven days by dialing 1-800-633-8284 and entering the reservation number above. The conference call and slide presentation will be available through a live webcast at www.myriad.com.

ADVERTISEMENT

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Media Contact:

Investor Contact:

Glenn Farrell

Matt Scalo

(385) 318-3718

(801) 584-3532

PR@myriad.com

IR@myriad.com